SpyGlass Pharma Unveils 6-Month Data from the First-In-Human Trial of Its Innovative Drug Delivery Platform for Chronic Eye Conditions

Posted: February 6, 2023 at 12:50 am

Data from a First-in-Human feasibility trial to treat glaucoma continues to demonstrate a 45% reduction in mean intraocular pressure at 6 months. Malik Y. Kahook, M.D. presented the compelling 6-month results during the New Horizons Forum at the Glaucoma 360 meeting in San Francisco. Data from a First-in-Human feasibility trial to treat glaucoma continues to demonstrate a 45% reduction in mean intraocular pressure at 6 months. Malik Y. Kahook, M.D. presented the compelling 6-month results during the New Horizons Forum at the Glaucoma 360 meeting in San Francisco.

Link:
SpyGlass Pharma Unveils 6-Month Data from the First-In-Human Trial of Its Innovative Drug Delivery Platform for Chronic Eye Conditions

Related Posts